Document:

<PAGE>
                                                                   EXHIBIT 10.71

This document contains confidential information which is not
being provided to the Public.

                    [BAXTER HEALTHCARE CORPORATION LETTERHEAD]

October 25, 2001

Mr. Frank Geiger
Senior Vice President
Coram, Inc.
1125 17th Street, Suite 2100
Denver, CO 80202

Re:  Coram / 34251865
     Pre-Filled Syringe & Rocephin Tier Pricing

Dear Mr. Geiger:

Your Medication Delivery (formally known as I.V. Systems) Purchase Agreement
with Baxter Healthcare Corporation indicates a Pre-Filled Syringe and Rocephin
price tier change on each November 1 and May 1.

Your Purchase Agreement states that Baxter shall review Coram's purchases of
flush syringes and frozen drug products every October 1 and April 1 of each
year. Based upon Coram's purchases during the six-month period, Coram's pricing
shall be adjusted to the applicable tier for purchases during the next period to
become effective on November 1 and May 1.

The Pre-Filled Syringe Tier shall remain at the initial pricing of Tier 2 per
the directive of Rose Lorella, ACT National Accounts Director, due to the
back-order situation that occurred in the preceding six-month period.

Based upon the total frozen sales for period April 1, 2001 through September 30,
2001 of Coram is now eligible for Rocephin Tier 1 pricing, committed volume of
in sales. Rocephin Tier 1 pricing shall become effective November 1, 2001.

Should you have any questions regarding this agreement, please contact Rose
Lorella, ACT National Accounts Director at (800) 285-3536 ext. 7597.

Sincerely,

/s/ HEATHER A. MARCELAIN

Heather A. Marcelain
Sales Contact Administrator

cc: Rose Lorella
    Mary Maniscalco
    File<PAGE>
                                                                   EXHIBIT 10.72

                    [BAXTER HEALTHCARE CORPORATION LETTERHEAD]

                                                               Account# 34251865

                                   AMENDMENT

This Amendment dated this 28th day of January 2002, is between Baxter Healthcare
Corporation with offices at Route 120 and Wilson Road, WG1-3S, Round Lake, IL
60073 ("Baxter") and Coram, Inc., with offices at 1675 Broadway, Suite 900,
Denver, CO 80202 ("Facility").

This Addendum will be in effect for forty-five (45) days for your consideration.

Baxter and Facility entered into a Purchase Agreement dated October 23, 2000
(the "Agreement").

Baxter and Facility agree to amend the Agreement as follows:

1.       Paragraph 9, is amended to provide that payment terms shall be 2%, 20
         net 30 days from invoice date through June 30, 2002. Beginning July 1,
         2002, payment terms will return to 2%, 15 net 30 days from invoice
         date.

2.       All other terms and conditions of the Agreement will remain in full
         force and effect.

3.       This Amendment shall become effective fifteen (15) calendar days from
         date on which Baxter countersigns this Amendment.

IN WITNESS WHEREOF, authorized representatives of the parties have executed this
Agreement.

CORAM, INC.                               BAXTER HEALTHCARE CORPORATION

BY: /s/ FRANK GEIGER                      BY:  /s/ LORI RUMER
   ---------------------------------         ---------------------------------
NAME:  Frank Geiger                       NAME:   Lori Rumer
     -------------------------------           -------------------------------
TITLE: Sr. Vice President MM              TITLE: Sales Contract Administrator
      ------------------------------            ------------------------------
DATE:      2/1/02                         DATE:        2/7/02
     -------------------------------           -------------------------------

<PAGE>
                    [BAXTER HEALTHCARE CORPORATION LETTERHEAD]

February 7, 2002

Mr. Frank Geiger
Senior Vice President
Coram, Inc.
1675 Broadway, Suite 900
Denver, CO 80202

Re:  34251865 / Amendment
     Coram, Inc.

Dear Mr. Geiger:

Enclosed for your records is a copy of the countersigned Amendment between
Coram, Inc. and Baxter Healthcare Corporation.

This Amendment shall become effective February 22, 2002.

Should you have any questions, please feel free to contact Rose Lorella,
Director of National Accounts at (800) 285-3536 ext. 7597 or your Sales Contract
Administrator at (800) 388-4631 ext. 3346.

We appreciate having this opportunity to be of service to you.

Sincerely,

/s/ HEATHER MARCELAIN

Heather Marcelain
Sales Contract Administrator

Enclosure

cc: Rose Lorella
    Mike Buha
    File<PAGE>
                                                                   EXHIBIT 10.73

This document contains confidential information which is not
being provided to the Public.

Coram
1675 Broadway #900
Denver, CO 80202

Term of Agreement:         1/1/02 through 12/31/2002

Baxter Healthcare Corporation, through its BioScience division ("Baxter") is
extending to Coram ("Customer") the following pricing and purchase requirements
in Schedule A. This pricing is based on Customer's agreement to purchase the
quantities of therapeutics set forth on Schedule A in accordance to the terms
and conditions of this Agreement including those indicated on Schedule B of this
Agreement which are incorporated into and made a part of this Agreement.

In addition, Baxter agrees to sell the therapeutics to Customer and Customer
agrees to purchase the therapeutics for resale, distribution or use within the
United States to patients for whom Customer holds an active prescription for the
therapeutics and/or to whom Customer provides home care services. Customer
agrees to maintain all licenses necessary for the purchase and dispensing of
the prescription therapeutics (e.g., state pharmacy license, physician's
license, etc.) and will forward a copy of such license to Baxter upon request.
The therapeutics purchased under this Agreement are not for resale, barter or
trade to other purchasers of such therapeutics or for export without the prior
written consent of Baxter.

Your acceptance is to be indicated by returning the signed duplicate originals
of this Agreement by 12/31/01. Current Published List Prices will be applied to
all Coram orders received after 12/31/01.

     THIS AGREEMENT IS NOT VALID UNTIL SIGNED BY BAXTER AT ITS HOME OFFICE.

Coram                                       Baxter Healthcare Corporation
1675 Broadway #900                          1627 Lake Cook Road
Denver, CO 80202                            Deerfield, Illinois 60015

By: /s/ FRANK GEIGER                        By: /s/ PETER O'MALLEY
   ------------------------------------        ---------------------------------

Name: Frank Geiger                          Name: Peter O'Malley
     ----------------------------------          -------------------------------
       Authorized Representative                   Authorized Representative

Title: Senior Vice President,               Title: VP/GM
       Materials Management                      -------------------------------
       --------------------------------

Date: 12/28/01                              Date: 1/7/02
     ----------------------------------          -------------------------------
<PAGE>
                                                                           CORAM

                                   SCHEDULE A
                         PURCHASE AND PRICING AGREEMENT

THERAPEUTICS:

IMMUNE GLOBULIN INTRAVENOUS (HUMAN), GAMMAGARD(R) S/D
SOLVENT DETERGENT TREATED

IMMUNE GLOBULIN INTRAVENOUS (HUMAN) [IGIV], IVEEGAM(R) EN

<Table>
<Caption>
                                                                             VOLUME
       PRODUCT                     DESCRIPTION              COST           COMMITMENT

<S>                           <C>                       <C>                <C>
Gamagard(R) S/D 060-384          0.5 gram in 10 mL
  NDC # 00944-2620-01             With Filter Set

Gamagard(R) S/D 060-385          2.5 gram in 50 mL
  NDC # 00944-2620-01         With Administration Set

Gamagard(R) S/D 060-386          5.0 gram in 100 mL
  NDC # 00944-2620-03         With Administration Set

Gamagard(R) S/D 060-387         10.0 gram in 192 mL
  NDC # 00944-2620-04         With Administration Set

 Iveegam EN(R) 923400           5.0 gram in 100 mL
  NDC # 64193-250-50          With Administration Set
</Table>

              Manufactured by Immuno AG and distributed by Baxter.
<PAGE>
                                   SCHEDULE B
                            ATTACHMENT TO AGREEMENT
                              TERMS AND CONDITIONS

PAYMENT TERMS AND CONDITIONS
Payment terms are 1% 30 net 31 days from date of invoice. Customer shall pay
Baxter a service charge of 1-1/2% per month, 18% per year, (or the highest
amount allowed by law, if lower) on all amounts past due. In the event Customer
is delinquent in payment of any amounts to Baxter, whether or not related to
this Agreement, Baxter may, at its option, declare all amounts owed to it under
all agreements as due and payable immediately and terminate this Agreement.

TAXES
Customer shall be responsible for payment of all applicable state/local sales,
use, and/or gross receipts tax receipts resulting from transactions with Baxter
regardless of placement of liability for the tax by law.

ORDERING PROCEDURE
Orders may be placed by calling Baxter BioScience Customer Service at
800-423-2090 or faxed to 800-756-4952. Shipment against any purchase order does
not constitute acceptance by Baxter of the terms and conditions or prices
stipulated on the purchase order. Shipment of any order, including standing
orders, will be made in accordance with terms, conditions and prices in effect,
as stated herein, and shall be governed solely by the terms of the Agreement
notwithstanding any conflicting or additional terms contained in any purchase
order, unless otherwise agreed to in writing by all parties concerned. Baxter
cannot guarantee maximum product expiration dating on any Products upon
delivery. Specific dating needs may be discussed with Customer Service at time
of order placement.

SHIPPING INFORMATION
Freight terms are F.O.B. Destination, Customer's location, freight pre-paid.
Under normal conditions, shipment will be made within five (5) days after
receipt of order. Additional charges for emergency or overnight deliveries will
be the responsibility of Customer and will be added to the invoice. Baxter
shall use commercially reasonable efforts to fill orders, but shall not be
liable for non-performance or delays caused by a shortage of supply of raw
materials, manufacturing problems, delivery or labor problems, intervention of
any governmental authority or acts of regulatory agencies, fires, earthquakes,
acts of God or causes beyond its control, and Customer agrees that in such
events Baxter, without liability to Customer, may allocate products among all
of its customers. Baxter's available supply will be made available on a
pro-rata basis to customers with firm commitments. In the event Baxter is
notified of and is able to verify a decision which changes the purchase and
delivery of Products for a patient or a group of patients either to or from
Customer, then to the extent it is able to verify a decision which changes the
purchase and delivery of Products for a patient or a group of patients either
to or from Customer, then to the extent it is able to, Baxter may have to make
appropriate adjustment in the supply of Products provided Customer.

DISPUTED INVOICES: An amount in dispute should be deducted from Customer's
remittance. PLEASE EXPLAIN THE DEDUCTION ON A LEGIBLE COPY OF THE INVOICE AND
ENCLOSE IT WITH THE PAYMENT. Baxter's Account Services Representative will work
with Customer to resolve the discrepancy.

DAMAGE OR SHORTAGE IN SHIPMENT: Baxter exercises extreme care in packing
shipments. To minimize the possibility of error, all orders should be counted
and inspected prior to acceptance of delivery from the carrier. ANY DAMAGE,
SHORTAGE OR OVERAGE SHOULD BE NOTED ON COPY OF THE CARRIER'S FREIGHT BILL AND
THE DRIVER SHOULD COUNTERSIGN THE DOCUMENT. If the damage is excessive do not
accept the shipment. Mark on the carrier's freight bill, "Shipment refused,
damaged. Return to shipper. "Baxter's Customer Service Department should be
notified immediately at 1-800-423-2090. Customer's cooperation in providing this
information will enable Baxter to expedite the necessary adjustments.

PROOF OF DELIVERY: Proof of delivery will be provided. If a request is received
within 90 days of date of shipment due to the expenses involved in obtaining
proof of delivery requests are subject to a $40.00 service fee. In the event
that proof of delivery cannot be provided, no service fee will be charged and
full credit will be issued to Customer's account.

RETURN GOODS POLICY
Baxter can accept for credit only those Products that do not perform
satisfactorily under the specified condition. Products which may have been
damaged during transportation, or which Customer may have received in error. Due
to the biological nature of the Products and the government regulations
involved, return of the Products must be authorized before any returns will be
accepted. Customer shall contact Baxter Customer Service for instructions on
the return procedure to be followed.

WARRANTY
Baxter Healthcare Corporation and its affiliates warrant that products shipped
or delivered to Customer will not, at the time of shipment by Baxter or its
affiliates, be adulterated or misbranded within the meaning of the Federal
Food, Drug and Cosmetic Act, as amended, nor will such product be an article
which may not, under provisions of sections 404 and 505 of said act, be
introduced into interstate commerce. Baxter and its affiliates further
represent and warrant that all product delivered to Customer when stored and
used in accordance with the directions on the labeling, are fit for the
purposes and indications described in the labeling. Unless the product is used
in accordance with its instructions, these warranties are void and of no
effect. THERE ARE NO OTHER EXPRESSED OR IMPLIED WARRANTIES, INCLUDING ANY
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. BAXTER AND ITS
AFFILIATES' SOLE OBLIGATION AND CUSTOMER'S EXCLUSIVE REMEDY FOR BREACH OF ANY
WARRANTY SHALL BE, AT BAXTER'S OPTION, TO REPAIR OR REPLACE THE PRODUCT.
NEITHER BAXTER NOR ITS AFFILIATES SHALL BE LIABLE FOR PROXIMATE, INCIDENTAL,
CONSEQUENTIAL OR EXEMPLARY DAMAGES. MORE WARRANTIES MAY ACCOMPANY INDIVIDUAL
PRODUCTS.

OTHER DISCOUNTS
Customer acknowledges the dollar value of any products or services which
Customer receives but does not pay for shall be a "discount or other reduction
in price" and may be subject to the disclosure requirements of Section
1128(b)(3)(A) of the Social Security Act. Customer shall disclose this discount
or reduction in price under any state or federal program that provides cost or
charge-based reimbursement to the participating institution for products or
services covered in this price list.

TRACE SALES REPORTS
On all purchases from Baxter BioScience, customer agrees to maintain complete
and accurate records of the sales of all Baxter BioScience products covered
under this Agreement. Customer agrees to provide monthly trace sales reports,
to include the following information:

     o    City, state, and the zip code of the prescribing physician

     o    # of units, unit of measure, Baxter Bioscience product code or NDC#,
          ship date

THE ABOVE INFORMATION MUST BE RECEIVED WITHIN FIVE (5) BUSINESS DAYS FOLLOWING
THE LAST DAY OF EACH CALENDAR MONTH.

The preferred method is to put your report in Microsoft Excel Spreadsheet
format along with a contact name and telephone number. Remit spreadsheet to the
following:

                             Gregg_Caya@baxter.com
                              1627 Lake Cook Road
                              Deerfield, IL 60015
                                Ph# 847.948.3555
                               Fax# 847.940.5798

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}]]